

iZafe publishes prospectus due to the forthcoming rights issue of units

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.

iZafe Group AB (publ) (“iZafe” or the “Company”) has prepared an EU growth prospectus (“The Prospectus”) for the forthcoming issue of units consisting of shares and warrants with preferential rights for existing shareholders, which was resolved on and announced on September 6, 2021 (the “Rights Issue”) as well as approved by the extraordinary general meeting on September 23, 2021. The Prospectus was approved and registered by the Swedish Financial Supervisory Authority today. The prospectus is now available on the Company’s website, www.izafe.se, and will be made available on Mangold Fondkommission AB’s website, www.mangold.se, as well as the Swedish Financial Supervisory Authority’s website, www.fi.se.

The Prospectus has been prepared due to the forthcoming issues of units with preferential rights and was approved and registered by the Swedish Financial Supervisory Authority as of today, September 24, 2021. The Prospectus, containing the full terms and conditions and other information about the Rights Issue is available on the Company’s website, www.izafe.se, as of today, September 24, 2021. The Prospectus will also be made available on Mangold Fondkommission AB’s website, www.mangold.se, as of October 4, 2021. Subscription forms and other information regarding the Rights Issue will be made available on the Company’s and Mangold Fondkommission AB’s website as of October 4, 2021. The Prospectus will also be available on the Swedish Financial Supervisory Authority’s website, www.fi.se.

The record date for obtaining unit rights is September 30, 2021. The subscription period will run from October 4, 2021 to October 18, 2021.

Advisors

Mangold Fondkommission AB is the financial advisor to iZafe in connection with the Rights Issue. Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the Rights Issue.

Important information

Release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions according to law and people in those jurisdictions, in which this press release has been announced or distributed, should inform themselves of and follow such legal restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in iZafe in any jurisdiction. Invitation to the persons concerned to participate in the Rights Issue will only take place through the EU growth prospectus which the Company has published in connection with the Rights Issue.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed in or into the United Kingdom, the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Switzerland, South Africa or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.

Within the European Economic Area, no offer is made to the public of securities in any country other than Sweden. In other Member States of the European Union, such an offer may only be made in accordance with the exceptions in the Prospectus Regulation (EU) 2017/1129.

This press release contains certain forward-looking information that reflects the Company's present view of future events as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development and actual outcomes may differ materially from the statements set forth in the forward-looking information.

Contacts

Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: ir@izafegroup.com
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company's digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: info@fnca.se. Further information is available at www.izafe.se/investor-relations/.

Attachments

[iZafe publishes prospectus due to the forthcoming rights issue of units](#)